论文部分内容阅读
目的:比较含紫杉醇或奥沙利铂的联合化疗方案一线治疗晚期胃癌的近期疗效、远期疗效及不良反应,并对两类方案的安全性进行评价。方法:84例晚期胃癌患者分为A、B两组,A组44例,采用紫杉醇联合氟脲嘧啶及顺铂的化疗方案;B组40例,采用奥沙利铂联合氟尿嘧啶的化疗方案。两组患者接受化疗均至少2周期,每2周期评判一次治疗效果。结果:A组客观有效率、疾病控制率、中位疾病进展时间、中位生存期、1年生存率分别为50%、84.1%、7.0个月、11.2个月和34.2%;B组分别为50%、75%、6.5个月、10.8个月和33.6%。A、B两组间比较,在客观有效率与生存期方面无显著性差异(P>0.05)。A组主要不良反应为血液学毒性和脱发,B组主要不良反应为外周神经毒性。结论:以紫杉醇或奥沙利铂为主的联合化疗方案治疗晚期胃癌,均有较好近期和远期疗效,两种方案疗效无显著差异,不良反应的特点有差别,但均可耐受,可根据患者个体的状况选择应用。
OBJECTIVE: To compare the short-term curative effect, long-term curative effect and side effects of first-line chemotherapy with paclitaxel or oxaliplatin in the treatment of advanced gastric cancer and to evaluate the safety of the two types of regimens. Methods: Eighty-four patients with advanced gastric cancer were divided into two groups: A and B, 44 patients in group A received chemotherapy with paclitaxel combined with fluorouracil and cisplatin, and 40 patients in group B received chemotherapy with oxaliplatin plus fluorouracil. Two groups of patients received chemotherapy for at least 2 cycles, every 2 cycles to judge the treatment effect. Results: The objective effective rate, disease control rate, median disease progression time, median survival time and 1-year survival rate in group A were 50%, 84.1%, 7.0 months, 11.2 months and 34.2% 50%, 75%, 6.5 months, 10.8 months and 33.6%. A, B between the two groups, there is no significant difference in objective efficiency and survival (P> 0.05). The main adverse reactions in group A were hematological toxicity and alopecia. The main adverse reactions in group B were peripheral neurotoxicity. Conclusion: Both paclitaxel and oxaliplatin-based combination chemotherapy regimen have good short-term and long-term curative effects. There is no significant difference between the two regimens in curative effect, but the characteristics of adverse reactions are different, but both are tolerable, According to the status of individual patients choose to apply.